

# Decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable (terminated appraisal)

Technology appraisal guidance

Published: 23 November 2023

[www.nice.org.uk/guidance/ta932](https://www.nice.org.uk/guidance/ta932)

# Contents

Advice.....	3
Information.....	3

## Advice

NICE is unable to make a recommendation about the use in the NHS of decitabine–cedazuridine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable. This is because Otsuka Pharmaceuticals (UK) has confirmed that it does not intend to make an evidence submission for the appraisal. Otsuka Pharmaceuticals (UK) considers that there is not enough evidence to provide an evidence submission for this appraisal.

## Information

If NHS organisations wish to consider decitabine–cedazuridine for this indication, they should follow the advice on rational local decision making in the [NHS Constitution for England](#) and the [NHS Commissioning Board and Clinical Commissioning Groups \(Responsibilities and Standing Rules\) Regulations 2012](#). This outlines the approach that should be taken when there is no NICE guidance.

NICE will review the position if the company decides that it wants to make an evidence submission.

ISBN: 978-1-4731-5541-1